CER Daily Newsfeed

Medicare Coverage Of Medical Technologies In A New Era

(3/6, Sean R. Tunis, Grace M. Hatfield, Parashar B. Patel, Peter J. Neumann, Health Affairs Forefront) comments “...Medicare should provide predictable and timely pathways to coverage and reimbursement for new technologies while ensuring that there is robust evidence supporting those technologies. Potential reforms, such as eliminating the CED program, would remove key policy tools available to CMS. Instead, efforts should focus on more efficient post-market evidence generation, streamlined processes, flexible study designs, and robust data infrastructure.” Full

Datavant Launches Clinical Insights Platform for Providers, Payers in VBC

(3/6, Emma Beavins, Fierce Healthcare) reports “...‘In the current system, stakeholders do not have all of the information necessary to drive optimal results for the patient,’ [Datavant's Sachin Patel] said. ‘Across life sciences, health technology innovators, payers and providers, critical data remains siloed and unstructured, making it difficult to create a comprehensive, real-time picture of patient and member health and outcomes. This data fragmentation results in inefficiencies, patient safety issues, high costs and poor outcomes across the healthcare system.’” Full

Third Time Lucky? Eli Lilly and Eisai Get Another Shot At English Funding For Alzheimer’s Drugs

(3/6, Neena Brizmohun, Pink Sheet) reports “...In an unusual decision by NICE, the health technology assessment institute for England is giving Eli Lilly and Eisai a third chance to persuade it to reimburse their respective disease-modifying treatments for Alzheimer’s disease, Kisunla (donanemab) and Leqembi (lecanemab). The move comes after NICE for the second time provisionally recommended against making either drug available via the National Health Service because they are too expensive.” Subscription Required